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RESUMO 
Introdução: Após uma trombose dos seios venosos cerebrais (TSV), o 
risco de recorrência trombótica está aumentado. O tempo até um segundo 
evento trombótico e os factores de risco associados à recorrência não 
foram adequadamente avaliados em estudos prospectivos. 
Métodos: Foram utilizados dados do International Study on Cerebral Vein 
and Dural Sinus Thrombosis (ISCVT) que incluiu 624 doentes com TSV 
seguidos durante um período de tempo com mediana de 13,9 meses. Os 
parâmetros de medida incluíram todos os eventos trombóticos venosos ou 
arteriais recorrentes sintomáticos, incluindo recorrência de TSV. Os 
potenciais preditores de recorrência, que incluíram características 
demográficas, achados imageológicos, anomalias trombofílicas, outros 
factores de risco para TSV e anticoagulação, foram avaliados por análise 
de sobrevivência usando o método de Cox. 
Resultados: Dos 624 doentes incluídos, 43 (6,9%) teve pelo menos uma 
recorrência trombótica. A taxa de recorrência foi de 5,1 por 100 pessoa-
anos para qualquer tipo de recorrência após a TSV inicial, 4,1 por 100 
pessoa-anos para eventos tromboembólicos venosos, 1,5 por 100 pessoa-
anos para recorrência de TSV e 0,8 por 100 pessoa-anos para eventos 
trombóticos arteriais. De todos os eventos trombóticos, 65,2% (n=30) 
ocorreram no primeiro ano. Vinte e quatro (63,2%) eventos 
tromboembólicos venosos e 9 (64,3%) recorrências de TSV aconteceram 
no primeiro ano. O sexo masculino (HRs= 2,6; 95% CI, 1,4–5,1; p=0,004) e 
a presença de policitémia/trombocitémia (HRs= 4,4; 95% CI, 1,6–12,7; 
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p=0,005) foram os únicos factores associados a um aumento significativo 
de eventos tromboembólicos venosos na análise multivariada.  
Conclusão: O risco de recorrência é baixo para uma segunda TSV, mas é 
moderado quando se consideram os outros eventos tromboembólicos 
venosos. Os doentes do sexo masculino e com policitémia/trombocitémia 
têm mais frequentemente eventos tromboembólicos venosos após TSV. 
 
Palavras-chave: Trombose dos seios venosos cerebrais; recorrência 
trombotica; tromboembolismo venoso; anticoagulação. 
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ABSTRACT 
Introduction: After cerebral vein and dural sinus thrombosis (CVT) there is 
an increased risk of further thromboembolic events. Time to a second 
cerebral or systemic thrombotic event and risk factors for recurrence have 
not been investigated in large prospective studies. 
Methods: Data was collected from the International Study on Cerebral Vein 
and Dural Sinus Thrombosis (ISCVT), which included 624 CVT patients 
followed up for a median of 13.9 months. Outcome measures included all 
symptomatic venous or arterial thrombotic events, including CVT 
recurrence. Potential predictors of recurrence including demographic 
characteristics, imaging features, thrombophilic abnormalities, other risk 
factors for CVT and anticoagulation were analyzed by Cox survival analysis. 
Results: Of the 624 included patients, 43 (6.9%) had at least one recurrent 
thrombotic event.  The rate of recurrence was 5.1 per 100 person-years for 
any thrombotic event after the initial CVT, 4.1 per 100 person-years for 
venous thromboembolic events (VTEs), 1.5 per 100 person-years for CVT 
recurrence and 0.8 per 100 person-years for arterial thrombotic events. Of 
all thrombotic events, 65.2% (n=30) occurred within the first year. Twenty-
four (63.2%) VTEs and 9 (64.3%) CVT recurrences occurred within the first 
year. Male gender (HRs= 2.6; 95% CI, 1.4–5.1; p=0.004) and 
polycythemia/thrombocythemia (HRs= 4.4; 95% CI, 1.6–12.7; p=0.005) 
were the only factors associated with a significant higher risk of VTEs in 
multivariate survival analysis. 
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Conclusion: The risk of recurrence of CVT is low, but is moderate for other 
VTEs. Recurrence of venous thrombosis after CVT is more frequent among 
men and in patients with polycythemia/thrombocythemia. 
 
Key words: cerebral vein and dural sinus thrombosis; thrombotic 
recurrence; venous thromboembolism; anticoagulation. 
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INTRODUCTION 
Cerebral vein and dural sinus thrombosis (CVT) is a cerebrovascular 
disease characterized by the presence of a thrombus within a cerebral vein 
or dural sinus, causing a partial or total occlusion and preventing normal 
venous blood flow.1,2,3 It is very often seen as a challenging neurological 
condition due to the variable clinical presentation and outcome. This 
heterogeneity may be explained by the complex pathophysiological 
mechanisms involved in CVT.2 The obstruction of blood flow within the 
cerebral vein causes focal damage as result of the localized edema, 
parenchymal infarction or hemorrhagic lesions. On the other hand, the 
blockage of cerebrospinal fluid by occlusion of a dural venous sinus explains 
the development of intracranial hypertension, usually associated with this 
illness.  
The estimated yearly incidence of CVT is 3 to 5 cases per million 
among adults2 and around 7 cases per million in children or neonates4. It is 
clinically classified as a rare type of stroke and contributes to less than 1% 
of all cerebrovascular events.3 In opposition to arterial stroke, it most often 
affects children as well as young to middle-aged adults. It is also more 
common in women, particularly during their fertile years. 
In approximately 85% of the CVT cases, the cause or a predisposing 
factor can be identified.5,6 In fact, CVT should be regarded as a multifactorial 
disease as more than one cause or risk factor is found in almost half of the 
patients.5 Nevertheless, it is important to know that after extensive 
investigation, 15-20% of the cases are considered cryptogenic CVT 
because no cause or risk factor was found.5,6 When present, the etiological 
factors associated with CVT are often separated into inherited or acquired 
as well as infective or non-infective.7 Despite important, this division is not 
very helpful when evaluating future management. The risk of a new 
thrombotic event and the duration of treatment depend on whether the risk 
factor is transient or permanent. Inherited or acquired prothrombotic 
disorders, cancer and certain hematological conditions are examples of 
permanent risk factors. On the other hand, infections, mechanical 
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precipitants, pregnancy/puerperium and drugs, such as oral contraceptives, 
are transient or precipitating factors.7  
The diagnosis of CVT requires a high degree of suspicion and is very 
often delayed.8 Although not specific, the most common symptoms and 
signs at presentation are headache, focal neurological deficits, papilledema, 
seizures and altered conscious state.9,10 Because of the clinical difficulties, 
neuroimaging studies are determinant establishing the definitive diagnosis. 
Nowadays, magnetic resonance imaging (MRI) is the modality of choice but 
computed axial tomography (CT) or in selected cases conventional cerebral 
angiography can also be used.2,3,11  
The current treatment of acute CVT includes anticoagulation because 
it may reduce the risk of fatal outcome, severe disability and thrombotic 
recurrence without promoting a significant increase in hemorrhagic 
lesions.2,3,12,13 
The increasing awareness of the condition along with the recent 
diagnostic and treatment advances have modified the clinical course of the 
disease. The prognosis of CVT is now more favorable than previously 
reported with an average rate of death or dependency of 15%5.   
 
Venous thromboembolic recurrences 
A potential long-term complication of CVT is the occurrence of new 
venous thromboembolic events (VTEs), including recurrent CVT.  
After an episode of CVT, the risk of a second cerebral or systemic 
venous thromboembolic event and the risk factors for recurrence are poorly 
known. Accurate data are needed to identify patients with a high risk of 
recurrence and to guide antithrombotic treatment after the acute phase of 
CVT.  
Current guidelines suggest oral anticoagulation therapy for three to 
twelve months after a first episode of CVT, depending on event-related 
	   11	  
features and thrombophilic characteristics.14 These recommendations are 
extrapolated from studies on extracerebral venous thrombosis, which may 
be inaccurate, since the risk of thrombotic events after CVT appears to be 
lower.15 
Previous studies report an overall recurrence rate after CVT of 2 to 
3% for another CVT and around 5% for any venous thromboembolic 
event.5,15,16,17,18 In a retrospective study, the presence of thrombophilic risk 
factors did not predict recurrent venous thrombosis after a CVT, and the risk 
of thrombotic recurrence was also not influenced by anticoagulant therapy.18 
However, in a recent pediatric cohort, G20210A prothrombin mutation and 
non-administration of anticoagulation before relapse were associated with 
recurrent venous thrombosis.19 
 
OBJECTIVE 
Using longitudinal data from the cohort of CVT patients of the 
International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT)5, 
the main objective of this work was to investigate recurrent thrombotic 
events after a first episode of CVT.  
The association between thrombotic recurrences with clinical imaging 
information, risk factors for CVT as well as with the duration of anticoagulant 
therapy was also studied. 
Part of the results of this study has been published in a peer-
reviewed journal.20 
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MATERIALS AND METHODS 
 
Study population 
This study includes all participants of the ISCVT cohort, a prospective 
multinational, multicentre, observational study that included 624 consecutive 
patients (aged >15 years) with symptomatic CVT, from 89 hospitals in 21 
countries.5 
 
Methods 
The diagnosis of CVT was confirmed by conventional angiography, 
CT venography, MRI combined with MR venography, surgery or autopsy, 
according to established diagnostic criteria.21 Demographic and clinical data, 
date of confirmation of the diagnosis by imaging (considered as day 0), the 
location and number of occluded sinus and veins were recorded. The 
etiologic workup for CVT was done by the local investigators, with the help 
of an attachment to the inclusion form. A systematic search for 
thrombophilia was performed in 75% of the participating centers. 
Thrombophilia screening included protein S, protein C, antithrombin III, 
G20210A mutation, factor V Leiden, methylenetetrahydrofolate reductase 
(MTHFR) mutation, lupus anticoagulant and anticardiolipin antibodies.  
Patients were categorized into four groups according to the identified 
risk factors for CVT: 1) those who only had transient risk factors (pregnancy 
or puerperium, infection, mechanical precipitants, oral contraceptives and 
other drugs with prothrombotic effect, recent surgery or dehydration); 2) 
those with only permanent risk factors (genetic or acquired thrombophilia, all 
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malignancies, polycythemia/thrombocythemia, severe anemia, vasculitis or 
other inflammatory prothrombotic systemic disorder); 3) patients with both 
transient and permanent risk factors; 4) patients without identifiable risk 
factors (cryptogenic CVT). 
Patients were followed up at six months, twelve months and yearly 
thereafter, the majority by direct interview and observation by the local 
investigators. Information about recurrent symptomatic CVT (new 
neurological symptoms with new cerebral venous occlusion on repeated CT 
venography or MRI) and other symptomatic venous or arterial thrombotic 
events (confirmed by appropriate studies decided by the individual clinician) 
was registered. For this study all new thrombotic events were analyzed after 
day 0, which occurred either during hospitalization for the initial CVT or 
during follow-up after discharge.  
The choice and duration of acute and post-discharge treatments was 
left to the decision of the treating physician, but all treatments and start-stop 
dates were recorded. Anticoagulation included intravenous or subcutaneous 
heparin in the acute phase and oral warfarin therapy (target international 
normalized ratio [INR] between 2.0 to 3.0). 
 
Statistical analysis 
The outcomes analyzed were: 1) any thrombotic event (arterial or 
venous); 2) any VTEs (recurrent CVT, lower limb deep vein thrombosis, 
pulmonary embolism, upper limb vein thrombosis, abdominal or pelvic 
venous thrombosis); 3) CVT recurrence; and 4) arterial thrombotic event 
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(ischemic stroke, transient ischemic attack, myocardial infarction or acute 
limb ischemia). 
The Kaplan-Meier method22 was used to calculate the cumulative 
incidence of the outcomes. In patients with more than one outcome event 
during the follow-up period, only the first event after the initial CVT was 
included for the survival curve analysis. The recurrence rate for each 
outcome measure was calculated as the number of events over the total 
number of person-years. The period of observation was calculated from day 
0 (diagnosis of initial CVT) until the outcome of interest, death or end of 
follow-up, whichever came first.  
As potential predictors of thrombotic recurrence, the following 
variables were selected a priori for the analysis: 1) demographic factors: age 
(analyzed as continuous variable and also dichotomized according to the 
median age of the cohort), elderly patient (≥ 65 years) and gender; 2) 
imaging features: location and number of occluded sinuses or veins 
(dichotomized as ≤ 2 and > 2 sinuses or veins involved); 3) thrombophilic 
risk factors: genetic or acquired thrombophilia, presence of specific genetic 
abnormalities (protein S, protein C, antithrombin III deficiencies, G20210A 
mutation, factor V Leiden and MTHFR mutation), the presence of more than 
one genetic risk factor, severe thrombophilia (presence of protein S, protein 
C, antithrombin III deficiencies, more than one genetic abnormality or 
antiphospholipid syndrome), or acquired trombophilia (antiphospholipid 
syndrome, nephrotic syndrome, hyperhomocysteinemia); 4) the four 
etiological groups described in the methods section, women ≤ 50 years of 
age on oral contraceptives, women with CVT during pregnancy or post-
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partum period and some etiologies known to be associated with increased 
risk of venous thromboembolism such as malignancy and 
polycythemia/thrombocythemia. 
Univariate Cox proportional-hazards models were used to calculate 
hazard ratios (HRs) and 95% CI’s for risk factors and to evaluate the impact 
of anticoagulation therapy on recurrence. Multivariate survival analysis was 
applied to identify independent risk factors associated with the outcome 
thrombotic recurrences of any type and VTEs. There were too few 
recurrences of CVT and new arterial thrombotic events to allow multivariate 
survival analysis. In the final statistical model it was included variables which 
contributed significantly (p≤0.05) to the outcome in the univariate analysis 
as well as variables that, even if not significant in the univariate analysis, 
were considered important for thrombotic recurrence on the basis of 
published data: age ≥ 65 years, male gender, malignancy, cryptogenic CVT, 
presence of thrombophilia and duration of oral anticoagulant therapy (days). 
Cox regression was done by a backward stepwise selection of variables and 
a p value of 0.05 was adopted as the limit for inclusion of a covariant. The 
analysis was not corrected for multiple comparisons. It was used SPSS 
Statistics 17.0 for Windows (SPSS Inc, Chicago, Ill) for all analyses. 
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RESULTS 
Six hundred and twenty-four patients were included in the present 
analysis. Information at the end of the study follow-up was available for 
98.7% of the patients. The median period of observation was 13.9 months 
(range 1 - 43.1 months). A total of 43 (6.9%) of the 624 patients had at least 
one thrombotic recurrence. A detailed distribution of the thrombotic 
recurrences after initial CVT is presented in Table 1.  
 
 
 
Table 1: Distribution of all thrombotic events after the initial cerebral vein 
and dural sinus thrombosis during the follow-up period. 
 
Months after initial CVT 
 
0 to 3 months 
n 
> 3 to 6 months 
n 
> 6 to 12 months 
n 
> 12 months 
n 
Total 
n 
VTEs 11 5 8 14 38 
CVT recurrence 1 4 4* 5 14 
Lower limb DVT 6* 1 3† 6 16 
Pulmonary embolism 1* 0 1* 2 4 
Upper limb DVT 2 0 0 1 3 
Mesenteric VT 1 0 0 0 1 
Arterial thrombotic events 3 2 1 2 8 
Ischemic stroke 1 1 0 0 2 
TIA 0 0 1 1 2 
Acute limb ischemia 2 1 0 1† 4 
All thrombotic recurrences 14 7 9 16 46 
*Two patients had two different venous thromboembolic events diagnosed during the same acute hospital 
admission. †One patient had two different thrombotic recurrences at different periods of time. 
Abbreviations: VTEs, Venous thromboembolic events; CVT, cerebral vein and dural sinus thrombosis; DVT, 
deep vein thrombosis; VT, venous thrombosis; TIA, Transient ischemic attack. 
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Twenty-one (45.6%) thrombotic recurrences occurred in the first six 
months and 30 (65.2%) within the first year. Two patients had two 
recurrences diagnosed during the same acute hospital admission (one had 
recurrent CVT and pulmonary embolism; the other had lower limb deep vein 
thrombosis and pulmonary embolism). One patient with acute limb ischemia 
later had deep leg vein thrombosis. Two patients suffered fatal thrombotic 
events (one recurrent CVT and one acute limb ischemia). The cumulative 
incidence of thrombotic recurrence after three and six months was 2.2% and 
3.4% respectively. Cumulative incidence gradually increased to 5.0% after 
one year, 7.9% after two years and 14.3% after three years (Figure 1). The 
rate per 100 person-years for any thrombotic event was 5.1. 
 
 
Figure 1: Kaplan-Meier estimation of all thrombotic events after the initial 
cerebral vein and dural sinus thrombosis. 
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A total of 36 (5.8%) of the 624 patients had at least one venous 
thromboembolic event. Sixteen (42%) VTEs occurred in the first six months 
and 24 (63.2%) within the first year. The cumulative probability of venous 
thrombotic recurrence was 1.7% at three months, 2.6% at six months, 4.0% 
at twelve months, 6.5% at two years and 12.8% at three years (Figure 2). 
The venous thromboembolic recurrence rate was 4.1 per 100 person-years.  
 
 
Figure 2: Kaplan-Meier estimation of venous thrombotic events after the 
initial cerebral vein and dural sinus thrombosis. 
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Fourteen (2.2%) patients had an episode of recurrent CVT. One 
patient suffered a fatal recurrent CVT. The cumulative incidence of a 
recurrent CVT event after three, six and twelve months was 0.2%, 0.9% and 
1.7%, respectively. The two-year cumulative incidence was 2.3% and 
increased to 5.7% at three years (Figure 3). Five (35.7%) of the total CVT 
recurrences occurred in the first six months and 9 (64.3%) within the first 
year. The CVT recurrence rate was 1.5 per 100 person-years. 
 
 
Figure 3: Kaplan-Meier estimation of recurrent cerebral vein and dural sinus 
thrombosis (CVT) after the inclusion event. 
 
 
	   20	  
Eight patients (1.3%) had a new arterial thrombotic event. The 
cumulative probability of an arterial thrombotic event was 0.5% at three 
months, 0.9% at six months, 1.1% at twelve months, 1.7% at one and two 
years (Figure 4). The rate of arterial thrombosis was 0.8 per 100 person-
years. 
 
Figure 4: Kaplan-Meier estimation of arterial thrombotic events after the 
initial cerebral vein and dural sinus thrombosis. 
 
The results of the univariate analysis of the effects of the 
demographic, imaging features, thrombophilic risk factors and other risk 
factors on the incidence of a recurrence are shown in Table 2.  
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Thrombotic recurrences 
 
Overall 
group 
(n=624) 
Recurrent CVT 
(Patients=14) 
All venous 
(Patients=36) 
All arterial 
(Patients=8) 
All events 
(Patients=43) 
 n (%) n (%) HR (95% CI) † n (%) HR (95% CI) ‡ n (%) HR (95% CI) ¥ n (%) HR (95% CI) ∂ 
Demographics      
Age > 37 312 (50.0) 4 (1.3) 0.4 (0.1–1.3) 19 (6.1) 1.2 (0.6–2.2) 7 (2.2) 7.3 (0.9–59.5) 25 (8) 1.4 (0.8–2.7) 
Age ≥ 65 51 (8.2) 0 (0) - 4 (7.8) 1.6 (0.6–4.5) 4 (7.8) 12.6 (3.2–50.8) § 8 (15.7) 3.0 (1.4–6.6) § 
Male gender 159 (25.5) 9 (5.7) 6.2 (2.1–18.6) § 16 (10.1) 2.7 (1.4–5.3) § 3 (1.9) 1.9 (0.5–7.9) 18 (11.3) 2.4 (1.3–4.5) § 
      
Imaging features      
Superior sagittal sinus 387 (62.1) 11 (2.8) 2.3 (0.6–8.3) 26 (6.7) 1.7 (0.8–3.4) 4 (1.0) 0.6 (0.2–2.5) 29 (7.5) 1.3 (0.7–2.5) 
Left lateral sinus 279 (44.8) 8 (2.9) 1.7 (0.6–4.8) 17 (6.1) 1.1 (0.6–2.1) 4 (1.4) 1.2 (0.3–4.8) 21 (7.5) 1.2 (0.6–2.1) 
Right lateral sinus 257 (41.3) 8 (3.1) 1.8 (0.6–5.3) 15 (5.8) 1.0 (0.5–1.9) 4 (1.6) 1.4 (0.4–5.7) 18 (7.0) 1.0 (0.5–1.8) 
Straight sinus 112 (18.0) 0 (0) - 4 (3.6) 0.6 (0.2–1.7) 1 (0.9) 0.7 (0.1–5.6) 5 (4.5) 0.6 (0.2–1.6) 
Cortical veins 107 (17.2) 1 (0.9) 0.4 (0.1–3.1) 6 (5.6) 1.1 (0.4–2.5) 0 (0) - 6 (5.6) 0.9 (0.4–2.0) 
Jugular veins 74 (11.9) 0 (0) - 1 (1.4) 0.2 (0–1.8) 1 (1.4) 1.1 (0.1–9.1) 2 (2.7) 0.4 (0.1–1.7) 
Deep venous system 68 (10.9) 1 (1.5) 0.7 (0.1–5.4) 2 (2.9) 0.5 (0.1–2.3) 1 (1.5) 1.4 (0.2–11.2) 3 (4.4) 0.7 (0.2–2.2) 
> 2 sinuses or veins 179 (28.7) 4 (2.2) 1.0 (0.3–3.2) 9 (5.0) 0.8 (0.4–1.8) 2 (1.1) 0.9 (0.2–4.3) 11 (6.1) 0.9 (0.4–1.7) 
      
Thrombophilic RF      
Any thrombophilia 214 (34.3) 3 (1.4) 0.4 (0.1–1.6) 15 (7.0) 1.2 (0.6–2.3) 4 (1.9) 1.7 (0.4–6.9) 18 (8.4) 1.2 (0.6–2.2) 
Genetic thrombophilia 140 (22.4) 2 (1.4) 0.5 (0.1–2.3) 11 (7.9) 1.4 (0.7–2.9) 4 (2.9) 3.2 (0.8–12.9) 14 (10.0) 1.6 (0.8–3.0) 
Protein S deficiency 33 (7.5) 1 (3.0) 1.3 (0.2–10.2) 2 (6.1) 0.8 (0.2–3.2) 1 (3.0) 2.2 (0.3–19.2) 3 (9.1) 1.0 (0.3–3.4) 
Protein C deficiency 21 (4.8) 0 (0) - 1 (4.8) 0.7 (0.1–5.4) 0 (0) - 1 (4.8) 0.6 (0.1–4.5) 
Antithrombin deficiency 4 (0.9) 0 (0) - 0 (0) - 0 (0) - 0 (0) - 
Factor V Leiden 33 (7.5) 1 (3.0) 1.8 (0.2–14.4) 2 (6.1) 1.1 (0.3–4.5) 1 (3.0) 2.5 (0.3–21.6) 3 (9.1) 1.4 (0.4–4.5) 
Prothrombin G20210A 37 (8.4) 0 (0) - 4 (10.8) 1.9 (0.7–5.5) 2 (5.4) 5.7 (1.0–31.2) § 5 (13.5) 2.0 (0.8–5.2) 
MTHFR mutation 43 (9.9) 0 (0) - 2 (4.7) 0.7 (0.2–2.8) 1 (2.3) 1.6 (0.2–13.8) 2 (4.7) 0.5 (0.1–2.3) 
> 1 genetic RF 36 (7.7) 1 (2.8) 1.3 (0.2–10.1) 2 (5.6) 0.8 (0.2–3.5) 2 (5.6) 5.8 (1.1–32.0) § 3 (8.3) 1.1 (0.3–3.6) 
Severe thrombophilia 102 (16.3) 1 (1.0) 0.3 (0.1–2.3) 4 (3.9) 0.5 (0.2–1.4) 3 (2.9) 2.8 (0.7–11.6) 6 (5.9) 0.7 (0.3–1.6) 
Acquired thrombophilia 98 (15.7) 1 (1.0) 0.3 (0–2.5) 6 (6.1) 0.9 (0.4–2.1) 1 (1.0) 0.7 (0.1–5.5) 7 (7.1) 0.8 (0.4–1.9) 
      
Etiological group      
Transient RF only 216 (34.6) 5 (2.3) 1.1 (0.4–3.4) 9 (4.2) 0.7 (0.3–1.4) 0 (0) - 9 (4.2) 0.5 (0.3–1.1) 
Pregnancy/Puerperium* 77 (20.2) 0 (0) - 4 (5.2) 1.4 (0.4–4.2) 0 (0) - 4 (5.2) 1.3 (0.4–3.8) 
Oral contraceptives* 207 (54.3) 3 (1.4) 2.4 (0.2–22.7) 7 (3.4) 0.6 (0.2–1.6) 0 (0) - 7 (3.4) 0.5 (0.2–1.4) 
Permanent RF only 138 (22.1) 3 (2.2) 1.0 (0.3–3.4) 12 (8.7) 1.8 (0.9–3.5) 3 (2.2) 2.1 (0.5–8.7) 15 (10.9) 1.9 (1.0–3.6) § 
Malignancy 46 (7.4) 0 (0) - 0 (0) - 1 (2.2) 2.2 (0.3–18.2) 1 (2.2) 0.4 (0–2.6) 
Poly/thrombocythemia 18 (2.9) 1 (5.6) 3.1 (0.4–24.1) 4 (22.2) 4.9 (1.7–14.0) § 0 (0) - 4 (22.2) 3.9 (1.4–11.1) § 
Transient+Permanent RF 192 (30.8) 3 (1.6) 0.5 (0.1–1.9) 10 (5.2) 0.8 (0.4–1.6) 3 (1.6) 1.3 (0.3–5.5) 12 (6.3) 0.8 (0.4–1.5) 
Cryptogenic CVT 78 (12.5) 3 (3.8) 2.1 (0.6–7.5) 5 (6.4) 1.2 (0.5–3.2) 2 (2.6) 2.6 (0.5–12.9) 7 (9.0) 1.5 (0.7–3.4) 
*Analyses among 381 women ≤ 50 years of age. †Hazard ratios (HRs) represent the comparison between patients with and without CVT recurrence. 
‡Hazard ratios (HRs) represent the comparison between patients with and without VTEs. ¥ Hazard ratios (HRs) represent the comparison between 
patients with and without arterial trombotic events. ∂Hazard ratios (HRs) represent the comparison between patients with and without any thrombotic 
recurrence. §p-value ≤ 0.05. The percentages for each specific genetic abnormality were calculated using the number of performed tests as denominator. 
Abbreviations: CVT, cerebral vein and dural sinus thrombosis; VTEs, venous thromboembolic events (recurrent CVT, lower limb deep vein thrombosis, 
pulmonary embolism, upper limb vein thrombosis, abdominal or pelvic venous thrombosis); RF, risk factor. 
 
Table 2: Univariate Cox proportional hazards analysis of predictors for 
thrombotic events after initial cerebral vein and dural sinus thrombosis. 
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When age was analyzed as a continuous variable, no association 
was found for CVT recurrence (HRs= 0.9; 95% CI, 0.9–1.0; p=0.071) or 
VTEs (HRs= 1.0; 95% CI, 0.9–1.0; p=0.950). Male gender (HRs= 6.2; 95% 
CI, 2.1–18.6; p=0.001) was an important risk factor for CVT recurrence. 
Male gender (HRs= 2.7; 95% CI, 1.4–5.3; p=0.003) and 
polycythemia/thrombocythemia (HRs= 4.9; 95% CI, 1.7–14.0; p=0.003) 
were associated with an increased risk of venous thrombotic recurrence. In 
a recent meta-analysis, the presence of MTHFR mutation was not 
significantly associated with a higher risk of CVT.23 Therefore an additional 
analysis was performed on the role of genetic thrombophilia excluding the 
MTHFR mutation cases. However, no significant association was found 
between this genetic thrombophilia excluding MTHFR mutation and 
recurrent CVT (HRs= 0.6; 95% CI, 0.1–3.1; p=0.572) or VTEs (HRs= 1.3; 
95% CI, 0.6–2.8; p=0.533). 
The risk of thrombotic recurrence of any type was higher among 
elderly patients (HR= 3.0; 95% CI, 1.4–6.6; p=0.005), men (HR= 2.4; 95% 
CI, 1.3–4.5; p=0.004) and patients who had one permanent risk factor only 
(HR= 1.9; 95%CI, 1.0–3.6; p=0.043). The presence of 
polycythemia/thrombocythemia was also associated with an increased risk 
of all thrombotic recurrences (HR= 4.0; 95% CI, 1.4–11.1; p=0.009). 
In the acute phase, 520 (83.3%) patients received anticoagulation 
therapy in therapeutic dosages with intravenous heparin or subcutaneous 
low-molecular-weight heparin. Oral anticoagulation after acute heparin 
therapy was prescribed to 476 (76.3%) patients. Information about the end 
date of oral anticoagulant therapy was not available for five patients. In 
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those who continued anticoagulation, the median duration of treatment was 
7.5 months. Details about anticoagulation treatment in patients with and 
without recurrence are presented in Table 3.  
 
  Thrombotic recurrences 
 No recurrence* Recurrent CVT VTEs Arterial events Any event 
 n (%) n (%) n (%) n (%) n (%) 
Anticoagulation continued (n=476) 446 (93.7) 11 (2.3)† 30 (6.3)‡ 5 (1.0)§ 34 (7.1) 
3 months or less (n=36) 29 (80.6) 0 (0) 7 (19.4) 3 (8.3) 10 (27.8) 
Between 3 and 6 months (n=94) 89 (94.7) 2 (2.1) 5 (5.3) 1 (1.1) 6 (6.4) 
Between 6 and 12 months (n=205) 195 (95.1) 5 (2.4) 10 (4.9) 0 (0) 10 (4.9) 
12 months or more (n=136) 128 (94.1) 4 (2.9) 8 (5.9) 1 (0.7) 8 (5.9) 
 * For 5 of the 442 patients continuing anticoagulation the end date of therapy was not available. †Two of these patients had the 
CVT recurrence after finishing the anticoagulation regimen. ‡Nine of these patients had the CVT recurrence after finishing the 
anticoagulation regimen. §Three of these patients had the arterial event after finishing the anticoagulation regimen.  
Abbreviations: CVT, cerebral vein and dural sinus thrombosis; VTEs, venous thromboembolic events (recurrent CVT, lower limb 
deep vein thrombosis, pulmonary embolism, upper limb vein thrombosis, abdominal or pelvic venous thrombosis). 
 
Table 3: Anticoagulation after the acute phase of cerebral vein and dural 
sinus thrombosis in included patients with and without venous 
thromboembolic events. 
 
At the time of recurrence, 23 (53.5%) patients with any thrombotic 
event, 21 (58.3%) with VTEs, 9 (64.3%) with a CVT recurrence and 2 (25%) 
with an arterial thrombotic event were on anticoagulant therapy. Oral 
anticoagulation after the acute phase was not associated with a significantly 
lower risk of thrombotic recurrence of any type (HRs= 1.0; 95% CI, 0.5–2.1; 
p=0.946), VTEs (HRs= 1.4; 95% CI, 0.6–3.4; p=0.459), CVT recurrence 
(HRs= 1.0; 95% CI, 0.3–3.7; p=0.981) or arterial thrombotic recurrence 
(HRs= 0.4; 95% CI, 0.1–1.8; p=0.244). In patients on oral anticoagulation, 
the duration of anticoagulant therapy was also not significantly associated 
with thrombotic events of any type (HRs= 1.0; 95% CI, 0.99–1.00; p=0.579) 
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or venous thromboembolic recurrences (HRs= 1.0; 95% CI, 0.99–1.00; 
p=0.963). 
In the final Cox regression analysis model, male gender (HRs= 2.0; 
95% CI, 1.1–3.9; p=0.030) and polycythemia/thrombocythemia (HRs= 3.2; 
95% CI, 1.1–9.2; p=0.027) were associated with a higher risk of thrombotic 
recurrences of any type. For venous thrombotic recurrences, male gender 
(HRs= 2.6; 95% CI, 1.4–5.1; p=0.004) and polycythemia/thrombocythemia 
(HRs= 4.4; 95% CI, 1.6–12.7; p=0.005) were also the only significant 
independent risk factors.  
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DISCUSSION 
The main new findings of this study are the description of the risk of a 
recurrent cerebral or a new systemic thrombotic event after CVT and the 
identification of male gender and polycythemia/thrombocythemia as 
independent predictors of venous thromboembolism after CVT. The large 
number of included subjects from a variety of countries and centers, the 
prospective design and the good quality of follow-up data are the main 
strengths of this study. Limitations include the fact that local investigators 
decided the investigations for symptomatic extracerebral thrombotic 
recurrences and thrombophilia screening was not performed in 25% of the 
centers. The median follow up in the ISCVT study was 13.9 months. 
Considering that most patients suffering a CVT are relatively young and 
have a life expectancy of several decades, a study with a longer follow-up 
might detect more recurrent events and additional predictors. Furthermore, 
thrombotic recurrences were not centrally adjudicated. These two factors 
could, therefore, underestimate the number of outcome events. 
Patients with a first episode of a VTE of any kind are at an increased 
risk of further thrombotic episodes. This risk of venous thromboembolic 
recurrence not only varies with time after the initial event, but also depends 
on certain risk factors for recurrence. These factors are in some way 
different from the risk factors for the initial event and can be divided 
according to three main characteristics: a) patient-related features: male 
gender and certain molecular thrombophilias (antiphospholipid syndrome, 
antithrombin, protein C or protein S deficiency, homozygous factor V Leiden 
or prothrombin G20210 mutation and combined abnormalities); b) 
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associated features such as the presence of a cancer, a known temporary 
risk factor for VTE or history of a previous cryptogenic VTE; c) event-related 
features such as the initial location (proximal DVT and PE have a higher risk 
of thromboembolic recurrence than other locations).24 Information about risk 
factors for thrombotic recurrence after CVT is limited. One previous 
retrospective study did not identify any clinical predictor for recurrence18, but 
a recent small prospective study found a higher risk of venous thrombotic 
recurrence in males and in those with severe thrombophilia.25 When we 
compare the results of the present study with studies on extracerebral 
venous thrombosis, male gender has also been associated with a higher 
risk of venous thrombotic recurrence26, whereas the influence of aging is 
more controversial.24 It is important to note that a significant proportion of 
women had the initial CVT while on oral contraceptives and during 
pregnancy or post-partum period. These factors are established transient 
risk factors for venous thrombosis27,28 and could explain the lower rate of 
further thrombotic events among women. However, a significant difference 
in thrombotic recurrence could not be found between women with and 
without these gender-specific risk factors, which favors the existence of 
further variables involved. The association between polycythemia or 
thrombocythemia and venous thrombotic events is well established29 and it 
is now confirmed for CVT.  
Current European guidelines on the treatment of CVT after the acute 
phase propose different durations of oral anticoagulation therapy in the 
presence of transient risk factors, genetic thrombophilia or idiopathic CVT.14 
In the ISCVT cohort, the different etiological groups and the presence of 
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genetic or acquired thrombophilia was not associated with a higher risk of 
thrombotic recurrence. Nonetheless, it is difficult to interpret these findings 
because the modest number of patients with specific genetic prothrombotic 
conditions and the low event rate make this study underpowered to 
investigate the role of specific prothombotic conditions in the recurrence of 
venous events. In a pediatric CVT cohort, prothrombin G20210A mutation 
predicted recurrent venous thromboembolism.19 The same study also 
reported persistent venous occlusion as an independent predictor of venous 
thrombotic recurrence. Martinelli and colleagues25, in a recent prospective 
study found a significantly higher risk of venous thromboembolic recurrence 
in patients with severe thrombophilia (antithrombin, protein C or protein S 
deficiency, more than one thrombophilic abnormality and positive 
antiphospholipid antibodies) when compared to those without or with mild 
thrombophilia. These results were obtained from a study performed in a 
tertiary thrombosis centre and include a much higher rate of patients with 
thrombophilic conditions, which could explain the differences between both 
studies. It is, therefore, important to further investigate this particular finding 
and one possibility for a future project could be a meta-analysis evaluating 
genetic abnormalities in CVT patients and the risk of recurrent VTEs.  
Studies in adult CVT patients found that venous recanalization occurs 
mostly within four months after CVT irrespective of anticoagulation.30 
Furthermore, no significant differences in relapses or outcome were found in 
those with incomplete or no recanalization.31,32 In this study, baseline 
imaging features such as location and thrombus load were not associated 
with thrombotic recurrence.  
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The cumulative incidence of recurrent thrombosis after CVT at six, 
twelve and twenty-four months was 3.4%, 5.0% and 7.9%, respectively. The 
overall rate of all thrombotic recurrences in the ISCVT cohort was 5.1 per 
100 person-years. These recurrences had a fatal outcome in two patients 
(4.7%). Six months after a CVT, the likelihood of VTEs was 2.6% and the 
risk increased to 6.5% after two years. In the ISCVT cohort, it was found an 
overall rate of VTEs after CVT of 4.1 per 100 person-years. Regarding CVT 
recurrence, the cumulative probability increased in a similar way from 0.9% 
at six months to 2.3% at two years. The rate per 100 person-years of CVT 
recurrence found was 1.5. In a systematic review, Dentali and colleagues15 
calculated an overall rate of 2.8% for CVT recurrence and 3.7% for 
extracerebral venous thrombotic events but the results and duration of 
follow-up varied widely between studies. A retrospective study18 reported a 
CVT recurrence rate of 2.2 per 100 person-years and a rate of 5.0 per 100 
person-years for recurrent venous thromboembolism. Moreover, the majority 
of the recurrences occurred within the first year after CVT. More recently, a 
prospective study with a median follow-up of 72 months reported an overall 
incidence of 1.58% patients-year for VTEs after CVT and 0.53% patients-
year for recurrent CVT, despite a prevalence of thrombotic recurrences at 
16 months similar to the ISCVT cohort (1.3% for CVT and 3.0% for other 
manifestations of venous thromboembolism).25 In the same study, almost 
half of the recurrences occurred within the first year after discontinuation of 
anticoagulant therapy. In the ISCVT cohort, it was also found that 63.2% of 
VTEs and 64.3% of CVT recurrences occurred within the first year after 
CVT. In addition, there was a steady increase in the risk of outcome events 
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and the Kaplan Meier curves showed a rather linear relation to time. The 
relatively short period of observation and the smaller number of patients in 
follow-up at later time points might explain the high event rates found within 
the first year. The venous thrombotic recurrence rate in this study was 
similar to the rate found in smaller prospective studies17,33,34 but CVT 
recurrence was less frequent than two retrospective analyses16,35 (Table 4). 
Venous thrombosis after CVT seems to be less frequent than the recurrence 
rate reported after deep vein thrombosis or pulmonary embolism.36,37 One 
possible reason is the absence in CVT of the hydrostatic factor that can 
promote thrombosis in patients with predisposing conditions.  
 
 
 
Study 
Nº of patients 
with follow-up Length of follow-up 
CVT 
n (%) 
All VTEs 
n (%) 
Prospective     
ISCVT20 624 Median= 16 m; Mean= 18.6±11 m 14 (2.2) 38 (6.1) 
Martinelli et al25 145 Median= 6 y 5 (3.4) 15 (10.3) 
Kenet et al19* 384 Median= 36 m 13 (3.4) 22 (5.7) 
VENOPORT17** 84 Median= 12 m ; Mean= 12±7 m 0 5 (6) 
Breteau et al. 34 48 Median= 36 m; (range 12- 60 m) 0 3 (5.5) 
Baumgartner et al.30 33 12 m 0 0 
Rondepierre et al.33 18 31 m 0 1 (5.5) 
Retrospective     
Gosk-Bierska et al.18 154 Mean= 36±47 m 10 (6.5) 23 (14.9) 
Preter et al.16 77 Median= 63 m; Mean= 77.8 m 9 (11.7) 20 (26) 
Mehraein et al.28 82 Mean= 10 y 5 (6.1) Not reported 
Maqueda et al.35 54 Median= 2.4 y; Mean= 3.5 y 1 (1.9) 8 (14.8) 
*Study in patients aged < 18 years. **Prospective part of the study.                                                                              
Abbreviations: m, months; y, years; CVT, Cerebral vein thrombosis; VTEs, Venous thromboembolic events. 
 
 
Table 4: Studies investigating the frequency of recurrent thrombotic events 
after cerebral vein and dural sinus thrombosis. 
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Recent evidence suggests an association between venous 
thrombosis and subsequent arterial thrombotic events.38 In the current 
report, the risk of an arterial thrombotic event after CVT was 0.8 per 100 
person-years, considerably lower than that of venous thrombotic recurrence. 
This study could not find an association between anticoagulation or 
duration of anticoagulation and prevention of thrombotic recurrence. A 
significant number of patients (58.3%) had the thrombotic recurrence while 
on anticoagulation and the proportion was even higher (64.3%) among 
patients with recurrent CVT. These findings could be explained by 
differences in sample size and prognostic characteristics between 
individuals who continued anticoagulation and those who did not continue 
anticoagulant therapy. Furthermore, the level of anticoagulation with INR 
monitoring was not evaluated and could influence the results. Gosk-Bierska 
and colleagues8, also reported no benefit in survival or recurrence for those 
receiving oral anticoagulants, but a higher risk of recurrent events was found 
in children not taking anticoagulation.9 As previously mentioned, recent 
results also found a very high rate of recurrence within the first year after 
discontinuation of anticoagulant therapy.24 We need to be cautious when 
interpreting these results as all these observational studies did not have the 
appropriate design for the assessment of the efficacy and appropriate 
duration of anticoagulant therapy after the acute phase of cerebral venous 
thrombosis.  
In conclusion, the findings of this study suggest that CVT may be a 
different clinical entity when compared with deep vein thrombosis in respect 
to thrombotic recurrence. These results may have implications for current 
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clinical practice and future research. Knowing the risk of a thrombotic 
recurrence is important for patients, and also to guide secondary prevention. 
A systematic review including all new CVT studies and focusing on the risk 
factors for venous thrombotic recurrence after CVT, particularly genetic 
abnormalities, will provide important evidence for treatment guidance.  
Nevertheless, the efficacy and safety of short or extended anticoagulation 
after CVT should be adequately assessed by a randomized controlled trial.  
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